ObsEva Announces Second Quarter 2021 Financial Results and Business Update

Posted: August 5, 2021 at 1:55 am

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-

Read more:
ObsEva Announces Second Quarter 2021 Financial Results and Business Update

Related Posts